aTyr Pharma Gestione
Gestione criteri di controllo 4/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Sanjay Shukla
Amministratore delegato
US$1.3m
Compenso totale
| Percentuale dello stipendio del CEO | 43.2% |
| Mandato del CEO | 7yrs |
| Proprietà del CEO | 0.2% |
| Durata media del management | 5.9yrs |
| Durata media del Consiglio di amministrazione | 15.1yrs |
Aggiornamenti recenti sulla gestione
Recent updates
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point
Sep 09We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully
Jul 13
We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely
Feb 03Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
Oct 04Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
May 06We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate
Jan 04aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies
Sep 29aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease
Sep 13aTyr Pharma gains with FDA Fast Track status for lead asset
Aug 11We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully
May 10Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Jan 24aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis
Dec 28aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy
Sep 24Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Sep 23Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
May 22aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 25Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?
Feb 09
aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan
Jan 14ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study
Jan 04aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study
Dec 21aTyr Pharma (LIFE) Investor Presentation - Slideshow
Oct 31Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$64m |
| Jun 30 2024 | n/a | n/a | -US$58m |
| Mar 31 2024 | n/a | n/a | -US$54m |
| Dec 31 2023 | US$1m | US$561k | -US$50m |
| Sep 30 2023 | n/a | n/a | -US$43m |
| Jun 30 2023 | n/a | n/a | -US$45m |
| Mar 31 2023 | n/a | n/a | -US$45m |
| Dec 31 2022 | US$2m | US$561k | -US$45m |
| Sep 30 2022 | n/a | n/a | -US$46m |
| Jun 30 2022 | n/a | n/a | -US$41m |
| Mar 31 2022 | n/a | n/a | -US$39m |
| Dec 31 2021 | US$2m | US$510k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$30m |
| Jun 30 2021 | n/a | n/a | -US$29m |
| Mar 31 2021 | n/a | n/a | -US$25m |
| Dec 31 2020 | US$1m | US$470k | -US$16m |
| Sep 30 2020 | n/a | n/a | -US$17m |
| Jun 30 2020 | n/a | n/a | -US$16m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$664k | US$450k | -US$24m |
| Sep 30 2019 | n/a | n/a | -US$24m |
| Jun 30 2019 | n/a | n/a | -US$25m |
| Mar 31 2019 | n/a | n/a | -US$30m |
| Dec 31 2018 | US$1m | US$450k | -US$35m |
| Sep 30 2018 | n/a | n/a | -US$40m |
| Jun 30 2018 | n/a | n/a | -US$44m |
| Mar 31 2018 | n/a | n/a | -US$45m |
| Dec 31 2017 | US$2m | US$403k | -US$48m |
Compensazione vs Mercato: La retribuzione totale di Sanjay ($USD 1.30M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 1.46M ).
Compensazione vs guadagni: La retribuzione di Sanjay è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Sanjay Shukla (52 yo)
7yrs
Mandato
US$1,300,525
Compensazione
Dr. Sanjay S. Shukla, M.D. M.S. has been the Chief Executive Officer, President and Director at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. fro...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 7yrs | US$1.30m | 0.16% $ 426.0k | |
| Chief Financial Officer | 6.3yrs | US$677.84k | 0.025% $ 65.0k | |
| General Counsel & Corporate Secretary | 10.1yrs | US$651.28k | 0.027% $ 69.5k | |
| Founder | no data | Nessun dato | Nessun dato | |
| Vice President of Technical Operations | less than a year | Nessun dato | Nessun dato | |
| Director of Investor Relations & Corporate Communications | no data | Nessun dato | Nessun dato | |
| Vice President of Corporate Development | 4.8yrs | Nessun dato | Nessun dato | |
| VP of Human Resource | 2.9yrs | Nessun dato | Nessun dato | |
| Vice President of Research | no data | Nessun dato | Nessun dato | |
| Executive Director of Biologics Development & Manufacturing | no data | Nessun dato | Nessun dato | |
| Scientific Consultant | 5.9yrs | US$717.31k | Nessun dato |
5.9yrs
Durata media
62yo
Età media
Gestione esperta: Il team dirigenziale di ATYR è esperto e expertise (durata media dell'incarico 5.9 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 7yrs | US$1.30m | 0.16% $ 426.0k | |
| Independent Director | 19.2yrs | US$120.84k | 0.024% $ 61.8k | |
| Independent Director | 19.2yrs | US$61.20k | 1.31% $ 3.4m | |
| Member of Scientific Advisory Board | 15.1yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 15.3yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Chairman of the Board | 7.6yrs | US$92.20k | 0.067% $ 174.7k | |
| Member of Scientific Advisory Board | 15.2yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 5.3yrs | US$68.88k | 0.0072% $ 18.7k |
15.1yrs
Durata media
67yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di ATYR è composto da personale esperto e esperto (durata media dell'incarico 15.1 anni).